Pfizer and BioNTech are asking drug regulators in the United States for full approval for their COVID-19 vaccines.
The two companies announced on May 7 that they initiated a rolling submission for a biologics license application by submitting nonclinical and clinical data, including the most recent analyses from a phase three clinical trial, to the Food and Drug Administration (FDA) in the coming weeks.